Bacterial meningitis in the United States in 1995

New England Journal of Medicine

Volumn 337, Issue 14, 1997, Pages 970-976

  Schuchat, Anne ^a,b   Robinson, Katherine ^a   Wenger, Jay D ^a   Harrison, Lee H ^c   Farley, Monica ^d   Reingold, Arthur L ^e   Lefkowitz, Lewis ^f   Perkins, Bradley A ^b  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e California Emerging Infections Prog   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE IMMUNIZATION; ADOLESCENT; ADULT; ARTICLE; BACTERIAL MENINGITIS; CHILD; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INFECTION PREVENTION; LISTERIA MONOCYTOGENES; MAJOR CLINICAL STUDY; NEISSERIA MENINGITIDIS; PREVALENCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; HAEMOPHILUS VACCINES; HUMANS; INFANT; INFANT, NEWBORN; MENINGITIS, BACTERIAL; MIDDLE AGED; POPULATION SURVEILLANCE; UNITED STATES;

EID: 0030779037     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199710023371404     Document Type: Article

References (39)

1. Ward J, Lieberman JM, Cochi SL. Haemophilus influenzae vaccines. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. 2nd ed. Philadelphia: W.B. Saunders, 1994:337-86.
2. Cochi SL, Broome CV, Hightower AW. Immunization of US children with Hemophilus influenzae type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment. JAMA 1985;253:521-9.
3. Wenger JD, Hightower AW, Facklam RR, Gaventa S, Broome CV. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. J Infect Dis 1990;162:1316-23.
4. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6.
5. Takala AK, Peltola H, Eskola J. Disappearance of epiglottitis during large-scale vaccination with Haemophilus influenzae type B conjugate vaccine among children in Finland. Laryngoscope 1994;104:731-5.
6. Jonsdottir KE, Steingrimsson O, Olafsson O. Immunisation of infants in Iceland against Haemophilus influenzae type b. Lancet 1992;340:252-3.
7. Scheifele DW. Recent trends in pediatric Haemophilus influenzae type B infections in Canada: Immunization Monitoring Program, Active (IMPACT) of the Canadian Paediatric Society and the Laboratory Centre for Disease Control. Can Med Assoc J 1996;154:1041-7. [Erratum, Can Med Assoc J 1996;154:1319.]
8. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997;336:708-16.
9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 4th ed. Wayne, Pa.: National Committee for Clinical Laboratory Standards, 1997. (NCCLS document no. M7-A4.)
10. Fraser DW, Darby CP, Koehler RE, Jacobs CF, Feldman RA. Risk factors in bacterial meningitis: Charleston County, South Carolina. J Infect Dis 1973;127:271-7.
11. Fraser DW, Geil CC, Feldman RA. Bacterial meningitis in Bernalillo County, New Mexico: a comparison with three other American populations. Am J Epidemiol 1974;100:29-34.
12. Fraser DW, Mitchell JE, Silverman LP, Feldman RA. Undiagnosed bacterial meningitis in Vermont children. Am J Epidemiol 1975;102:394-9.
13. Schoendorf KC, Adams WG, Kiely JL, Wenger JD. National trends in Haemophilus influenzae meningitis mortality and hospitalization among children, 1980 through 1991. Pediatrics 1994;93:663-8.
14. Doern GV, Jorgensen JH, Thornsberry C, Preston DA, Haemophilus influenzae Surveillance Group. Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. Diagn Microbiol Infect Dis 1986;4:95-107.
15. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34:2075-80.
16. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-5.
17. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945;82:445-65.
18. Rodrigues LP, Schneerson R, Robbins JB. Immunity to Hemophilus influenzae type b. I. The isolation, and some physicochemical, serologic and biologic properties of the capsular polysaccharide of Hemophilus influenzae type b. J Immunol 1971;107:1071-80.
19. Gotschlich EC, Liu TY, Artenstein MS. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med 1969;129:1349-65.
20. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991;164:982-6.
21. Murphy TV, Pastor P, Medley F, Osterholm MT, Granoff DM. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr 1993;122:517-23.
22. Mohle-Boetani JC, Ajello G, Breneman E, et al. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 1993;12: 589-93.
23. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: an emerging threat. JAMA 1995;273:383-9.
24. Whalen CM, Hockin JC, Ryan A, Ashton F. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992: emergence of a virulent clone of Neisseria meningitidis. JAMA 1995;273: 390-4.
25. Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-5):1-10.
26. Frasch CE. Vaccines for the prevention of meningococcal disease. Clin Microbiol Rev 1989;2:Suppl:S134-S138.
27. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
28. Sierra GVG, Campa HC, Varcacel NW, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14:195-207.
29. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340:1074-8. [Erratum, Lancet 1992;340:1554.]
30. Pneumococcal and influenza vaccination levels among adults aged ≥65 years - United States, 1993. MMWR Morb Mortal Wkly Rep 1996; 45:853-9.
31. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Morb Mortal Wkly Rep 1996;45(RR-7):1-24.
32. Committee on Obstetric Practice. Prevention of early-onset group B streptococcal disease in newborns. ACOG committee opinion no. 173. Washington, D.C.: American College of Obstetricians and Gynecologists, 1996.
33. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn. Revised guidelines for prevention of early-onset group B streptococcal (GBS) infection. Pediatrics 1997;99:489-96.
34. Kasper DL, Paoletti LC, Wessels MR, et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996;98:2308-14.
35. Schuchat A, Deaver KA, Wenger JD, et al. Role of foods in sporadic listeriosis. I. Case-control study of dietary risk factors. JAMA 1992;267: 2041-5.
36. Tappero JW, Schuchat A, Deaver KA, Mascola L, Wenger JD. Reduction in the incidence of human listeriosis in the United States: effectiveness of prevention efforts? JAMA 1995;273:1118-22.
37. Serogroup Y meningococcal disease - Illinois, Connecticut, and selected areas, United States, 1989-1996. MMWR Morb Mortal Wkly Rep 1996;45:1010-3.
38. Blumberg HM, Stephens DS, Modansky M, et al. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis 1996;173: 365-73.
39. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333: 481-6.